DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Information source: Purdue Pharma LP
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Other Acute Postoperative Pain; Prolonged Endotracheal Intubation

Intervention: Buprenorphine IV (Drug)

Phase: Phase 3

Status: Withdrawn

Sponsored by: Purdue Pharma LP


The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy of intravenous (IV) buprenorphine in pediatric patients.

Clinical Details

Official title: A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged From Birth to 6 Years of Age (Inclusive) Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary outcome measures are clearance (CL/F) and apparent central volume of distribution (Vc/F) estimated using standard population nonlinear mixed effects methodology.

Secondary outcome: The number of participants with adverse events as a measure of safety.

Detailed description: A study of the PK, safety, and efficacy of IV buprenorphine in acute moderate to severe pain in male and female pediatric patients aged from birth to 6 years, inclusive, requiring continuous opioid analgesic treatment for at least 24 hours and up to 72 hours.


Minimum age: N/A. Maximum age: 6 Years. Gender(s): Both.


Inclusion Criteria include:

- Must have written informed consent provided by the parent or legal guardian and/or

patient assent, when appropriate

- Male and female children, from birth to aged 6 years, inclusive, with minimum weight

of 2. 5 kg

- Have or are anticipated to have acute moderate to severe pain; requiring treatment

with an intravenous (IV) opioid analgesic medication for at least 24 hours postoperatively or; due to prolonged endotracheal intubation requiring IV opioid analgesic treatment for at least 24 hours poststabilization

- Must have stable vital signs

- Must have stable respiratory status

- Must be inpatient for the treatment period of the study

Exclusion Criteria include:

- Have any known allergy or sensitivity to buprenorphine or other opioids (this

criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation])

- Have evidence of impaired renal function

- Have hepatic impairment

- Have history of seizures

- Have a history of sleep apnea within the past year

- Have structural heart disease or a pacemaker

- Have clinically unstable cardiac disease

- Have used any investigational medication/therapy within 30 days prior to the first

dose of study drug

- Are deemed to be unsuitable by the investigator for reason(s) not specifically stated

in the exclusion criteria. Other protocol-specific inclusion/exclusion criteria may apply.

Locations and Contacts

Additional Information

Product Information

Starting date: November 2011
Last updated: November 17, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017